<?xml version='1.0' encoding='utf-8'?>
<document id="27344633"><sentence text="Stability behaviour of antiretroviral drugs and their combinations. 3: Characterization of interaction products of emtricitabine and tenofovir disoproxil fumarate by mass spectrometry."><entity charOffset="115-128" id="DDI-PubMed.27344633.s1.e0" text="emtricitabine" /><entity charOffset="133-162" id="DDI-PubMed.27344633.s1.e1" text="tenofovir disoproxil fumarate" /><pair ddi="false" e1="DDI-PubMed.27344633.s1.e0" e2="DDI-PubMed.27344633.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27344633.s1.e0" e2="DDI-PubMed.27344633.s1.e1" /></sentence><sentence text="The present study investigated drug-drug interaction behaviour of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) under solid state stability test conditions"><entity charOffset="66-79" id="DDI-PubMed.27344633.s2.e0" text="emtricitabine" /><entity charOffset="81-84" id="DDI-PubMed.27344633.s2.e1" text="FTC" /><entity charOffset="90-119" id="DDI-PubMed.27344633.s2.e2" text="tenofovir disoproxil fumarate" /><entity charOffset="121-124" id="DDI-PubMed.27344633.s2.e3" text="TDF" /><pair ddi="false" e1="DDI-PubMed.27344633.s2.e0" e2="DDI-PubMed.27344633.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27344633.s2.e0" e2="DDI-PubMed.27344633.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27344633.s2.e0" e2="DDI-PubMed.27344633.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27344633.s2.e0" e2="DDI-PubMed.27344633.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27344633.s2.e1" e2="DDI-PubMed.27344633.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27344633.s2.e1" e2="DDI-PubMed.27344633.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27344633.s2.e1" e2="DDI-PubMed.27344633.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27344633.s2.e2" e2="DDI-PubMed.27344633.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27344633.s2.e2" e2="DDI-PubMed.27344633.s2.e3" /></sentence><sentence text=" Six interaction products were separated and detected by high performance liquid chromatography coupled to photodiode array detector (HPLC-PDA) using C18 column" /><sentence text=" The same were characterized using LC-high resolution mass spectrometry (LC-HRMS), LC-multi stage mass spectrometry (LC-MS(n)) and online hydrogen/deuterium (H/D) exchange studies"><entity charOffset="138-146" id="DDI-PubMed.27344633.s4.e0" text="hydrogen" /><entity charOffset="147-156" id="DDI-PubMed.27344633.s4.e1" text="deuterium" /><pair ddi="false" e1="DDI-PubMed.27344633.s4.e0" e2="DDI-PubMed.27344633.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27344633.s4.e0" e2="DDI-PubMed.27344633.s4.e1" /></sentence><sentence text=" The interaction pathway among the two drugs was outlined based on the elucidated structures" /><sentence text=" Four of the six interaction products were also formed in marketed tablets containing FTC and TDF (along with efavirenz (EFV)) that were kept without packing under accelerated condition of 40Â°C/75% RH till 6 months"><entity charOffset="110-119" id="DDI-PubMed.27344633.s6.e0" text="efavirenz" /><entity charOffset="86-94" id="DDI-PubMed.27344633.s6.e1" text="FTC" /><entity charOffset="94-102" id="DDI-PubMed.27344633.s6.e2" text="TDF" /><pair ddi="false" e1="DDI-PubMed.27344633.s6.e1" e2="DDI-PubMed.27344633.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27344633.s6.e1" e2="DDI-PubMed.27344633.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27344633.s6.e1" e2="DDI-PubMed.27344633.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27344633.s6.e2" e2="DDI-PubMed.27344633.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27344633.s6.e2" e2="DDI-PubMed.27344633.s6.e0" /></sentence><sentence text=" " /></document>